Evidence map›Paper›PMID 38968137›Full record

ArticleBlood advances2024

Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation.

Stephen P Persaud, Aditya R Yelamali, Julie K Ritchey, John F DiPersio

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stephen P PersaudDivision of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-7733-5509
Aditya R YelamaliDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0009-0003-9090-8505
Julie K RitcheyDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
John F DiPersioDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-0429-3133

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8M
NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R35 CA210084
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD47 AntigenHematopoietic Stem Cell TransplantationTransplantation ConditioningTransplantation, HomologousHumansJanus Kinase InhibitorsProto-Oncogene Proteins c-kitCD47 AntigenCD47 protein, humanJanus Kinase InhibitorsProto-Oncogene Proteins c-kit

Identifiers

PMID38968137
PMCPMC11395768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.